TransGenic Group

TransGenic Group R&D per Employee

The R&D Spending per Employee of TransGenic Group (2342.T) as of Nov 11, 2026 is 353,194.92 JPY. In the previous year, R&D Spending per Employee was 259,906.78 JPY — a change of 35.89% (higher).

R&D per Employee

353,194.92JPY

YoY

35.89%

Last updated:

R&D Spending per Employee of TransGenic Group is 2025 353,194.92 JPY. R&D Spending per Employee of TransGenic Group was 2024 259,906.78 JPY. It decreases by 35.89% higher compared to the previous year.

The TransGenic Group R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
233,711.86 JPY
Jan 1, 2019
218,656.78 JPY
Jan 1, 2020
162,355.93 JPY
Jan 1, 2021
113,457.63 JPY
Jan 1, 2022
170,381.36 JPY
Jan 1, 2023
160,186.44 JPY
Jan 1, 2024
259,906.78 JPY
Jan 1, 2025
353,194.92 JPY
The TransGenic Group R&D per Employee history
YEARR&D per EmployeeYoY
353,194.92JPY+35.89%
259,906.78JPY+62.25%
160,186.44JPY-5.98%
170,381.36JPY+50.17%
113,457.63JPY-30.12%
162,355.93JPY-25.75%
218,656.78JPY-6.44%
233,711.86JPY+14.87%
203,453.39JPY-6.88%
218,474.58JPY+27.50%
171,347.46JPY-5.00%
180,360.17JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TransGenic Group Stock analysis

What does TransGenic Group do? TransGenic Group Inc. generates revenue through three business segments. The Contract Research Organization (CRO) segment provides contract clinical tests for pharmaceuticals and foods, including pharmacodynamic and safety pharmacology tests, as well as non-clinical safety tests for pesticides and food. It also offers contract production of genetically modified mice and antibodies, sales of model mice, and development of new biomarkers. The Diagnostic Analysis segment delivers pathological diagnosis services, gene analysis contract services, and drug discovery support for individualized medicine. The TGBS segment provides business succession and revitalization advice and support services, alongside an electronic commerce (EC) business for retail and wholesale of electrical products. The CRO segment serves pharmaceutical and food companies requiring clinical and non-clinical testing services. The Diagnostic Analysis segment targets healthcare providers and researchers needing diagnostic and drug discovery support. The TGBS segment caters to businesses seeking succession planning and revitalization services, while its EC business sells electrical products to retail and wholesale customers. Revenue streams include fees from clinical and safety testing, production of genetically modified animals, sales of model mice, and development of biomarkers under the CRO segment. The Diagnostic Analysis segment earns from pathology services, gene analysis, and drug discovery support. The TGBS segment generates income through advisory services and EC sales of electrical products. TransGenic Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TransGenic Group stock

R&D Spending per Employee of TransGenic Group is 353,194.92 JPY in 2025.

R&D Spending per Employee of TransGenic Group changed from 259,906.78 JPY to 353,194.92 JPY, representing a 35.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee TransGenic Group since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's TransGenic Group historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — TransGenic Group

All Key Metrics — TransGenic Group